| 摘要 |
<p>Disclosed is the use of aclidinium, in the manufacture of a medicament for use in the treatment or prevention of a respiratory disease or condition in a patient by inhalation (such as acute or chronic bronchitis, emphysema, asthma and chronic obstructive pulmonary disease), without producing in said patient systemic antimuscarinic effects, wherein the patient is suffering from or susceptible to a condition which may be exacerbated by systemic antimuscarinic activity (such as schizophrenia, impaired concentration, confusion, agitation, delirium, attention deficit, impaired memory, respiratory depression, glaucoma, dry eye, increased pupil size, blurred vision, increased intraocular pressure, enlarged or obstructed prostate, difficulty urinating, narrowing or obstruction of the small intestine, enlarged colon, chronic constipation, enlarged lower esophagus, decreased gastric motility, constipation, dry mouth, throat irritation, impaired sweating, cardiovascular disease, arrhythmia, tachycardia, Parkinson's Disease, Alzheimer's Disease, dementia or myasthenia gravis).</p> |
